Prediction of outcome in breast cancer patients using test parameters from complete blood count
Prediction of outcome in breast cancer patients using test parameters from complete blood count
复制标题
使用全血细胞计数测试参数预测乳腺癌患者的结果
DOI：
10.3892/mco.2016.827
复制
发表时间：
2016-06-01
影响因子：
1.2
通讯作者：
Hu, Chengiin
中科院分区：
文献类型：
--
作者：
Zhang, Pingping;Zong, Yulong;Hu, Chengiin
本研究的目的是评估预处理全血细胞计数（CBC）检测参数对乳腺癌患者预后的预测作用。本研究共纳入162例长期随访的乳腺癌患者。回顾性收集治疗前CBC的红细胞指数（RCI）和嗜中性淋巴细胞比率（NLR）以及相关临床资料。我们评估了RCI和NLR与肿瘤大小、临床分期、组织学分级、雌激素受体、孕激素受体和人表皮生长因子受体2状态的关系。我们进一步进行了生存分析和考克斯多变量分析，根据RCI和NLR中位数分层，以评估其预后影响。在无病生存期（DFS）分析中，平均红细胞血红蛋白（MCH）和NLR较高组的患者与MCH和NLR较低组相比，DFS时间较短（MCH P=0.017，NLR P=0.039）。单因素分析显示，MCH和NLR均与DFS显著相关。考克斯多因素分析显示，只有MCH是疾病复发的独立预测因子（危险比= 1.975，95%可信区间：1.118-3.487，P=0.019），而没有任何指标与总生存期相关。我们的研究结果表明，MCH治疗前可能是一个预测指标与DFS乳腺癌。
The aim of this study was to evaluate the prognostic effect of test parameters from pretreatment complete blood count (CBC) for predicting outcome in breast cancer patients. A total of 162 patients with breast cancer and a long follow-up were enrolled in this study. Red cell indices (RCIs) and neutrophil-lymphocyte ratio (NLR) from CBC prior to treatment, as well as related clinical data, were retrospectively collected. We evaluated the association of RCI and NLR with tumor size, clinical stage, histological grade, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status. We further performed survival analysis and Cox multivariate analysis, stratified by RCI and NLR median values, to evaluate their prognostic effects. In the disease-free survival (DFS) analysis, patients in the higher mean corpuscular hemoglobin (MCH) and NLR groups exhibited shorter DFS times compared with those in the lower MCH and NLR groups (P=0.017 for MCH and P=0.039 for NLR). The univariate analysis revealed that both MCH and NLR were significantly associated with DFS. The Cox multivariate analysis demonstrated that only MCH was an independent predictor associated with disease relapse (hazard ratio = 1.975, 95% confidence interval: 1.118-3.487, P=0.019), whereas no index was associated with overall survival. Our results suggest that MCH prior to treatment may be a predictive marker associated with DFS in breast cancer.